Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

hologic inc. - HOLX

HOLX

Close Chg Chg %
61.32 0.45 0.73%

Closed Market

61.77

+0.45 (0.73%)

Volume: 2.04M

Last Updated:

Mar 31, 2025, 4:00 PM EDT

Trade Now

Company Overview: hologic inc. - HOLX

HOLX Key Data

Open

$61.36

 Day Range

61.05 - 62.18

52 Week Range

60.34 - 84.67

 Market Cap

$13.76B

Shares Outstanding

224.39M

 Public Float

222.47M

Beta

0.97

 Rev. Per Employee

N/A

P/E Ratio

19.40

 EPS

$3.19

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.63M

  

HOLX Performance

1 Week
 
 0.00%
 
1 Month
 
 -3.27%
 
3 Months
 
 -14.94%
 
1 Year
 
 -21.34%
 
5 Years
 
 86.84%
 

HOLX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 23
Full Ratings ➔

About hologic inc. - HOLX

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

HOLX At a Glance

Hologic, Inc.
250 Campus Drive
Marlborough, Massachusetts 01752
Phone 1-508-263-2900 Revenue 4.03B
Industry Medical Specialties Net Income 789.50M
Sector Health Technology Employees 7,063
Fiscal Year-end 09 / 2025
View SEC Filings

HOLX Valuation

P/E Current 19.401
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 24.318
Price to Sales Ratio 4.764
Price to Book Ratio 3.651
Price to Cash Flow Ratio 14.939
Enterprise Value to EBITDA 15.262
Enterprise Value to Sales 4.844
Total Debt to Enterprise Value 0.136

HOLX Efficiency

Revenue/Employee 570,621.549
Income Per Employee 111,779.697
Receivables Turnover 6.713
Total Asset Turnover 0.441

HOLX Liquidity

Current Ratio 3.686
Quick Ratio 3.031
Cash Ratio 2.25

HOLX Profitability

Gross Margin 55.524
Operating Margin 24.073
Pretax Margin 21.465
Net Margin 19.589
Return on Assets 8.631
Return on Equity 15.561
Return on Total Capital 10.137
Return on Invested Capital 10.298

HOLX Capital Structure

Total Debt to Total Equity 51.813
Total Debt to Total Capital 34.129
Total Debt to Total Assets 29.03
Long-Term Debt to Equity 50.55
Long-Term Debt to Total Capital 33.297
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Hologic Inc. - HOLX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
5.63B 4.86B 4.03B 4.03B
Sales Growth
+49.14% -13.66% -17.12% -0.00%
Cost of Goods Sold (COGS) incl D&A
1.88B 1.89B 1.81B 1.79B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
406.90M 430.10M 323.40M 309.00M
Depreciation
88.00M 89.20M 89.60M 99.30M
Amortization of Intangibles
318.90M 340.90M 233.80M 209.70M
COGS Growth
+20.21% +0.77% -4.53% -0.83%
Gross Income
3.75B 2.97B 2.22B 2.24B
Gross Income Growth
+69.57% -20.89% -25.14% +0.67%
Gross Profit Margin
+66.64% +61.07% +55.15% +55.52%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.27B 1.32B 1.28B 1.27B
Research & Development
276.30M 283.40M 294.30M 272.80M
Other SG&A
994.40M 1.04B 987.60M 994.80M
SGA Growth
+19.20% +3.99% -2.99% -1.12%
Other Operating Expense
- - - -
-
Unusual Expense
29.50M (11.50M) 233.90M 107.70M
EBIT after Unusual Expense
2.45B 1.66B 707.10M 862.50M
Non Operating Income/Expense
1.30M 23.60M 80.10M 124.70M
Non-Operating Interest Income
1.40M 12.90M 120.50M 108.70M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
93.60M 95.10M 111.10M 122.10M
Interest Expense Growth
-21.21% +1.60% +16.82% +9.90%
Gross Interest Expense
93.60M 95.10M 111.10M 122.10M
Interest Capitalized
- - - -
-
Pretax Income
2.36B 1.59B 676.10M 865.10M
Pretax Income Growth
+135.66% -32.73% -57.43% +27.95%
Pretax Margin
+41.92% +32.66% +16.78% +21.46%
Income Tax
491.40M 286.20M 220.10M 75.60M
Income Tax - Current - Domestic
538.30M 353.40M 296.50M 105.80M
Income Tax - Current - Foreign
23.20M 99.00M 32.70M 41.90M
Income Tax - Deferred - Domestic
(57.50M) (139.30M) (81.50M) (58.40M)
Income Tax - Deferred - Foreign
(12.60M) (26.90M) (27.60M) (13.70M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.87B 1.30B 456.00M 789.50M
Minority Interest Expense
- - - (1.80M)
-
Net Income
1.87B 1.30B 456.00M 789.50M
Net Income Growth
+67.82% -30.43% -64.98% +73.14%
Net Margin Growth
+33.23% +26.77% +11.31% +19.59%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.87B 1.30B 456.00M 789.50M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.87B 1.30B 456.00M 789.50M
EPS (Basic)
7.2808 5.1764 1.8479 3.3493
EPS (Basic) Growth
+71.53% -28.90% -64.30% +81.25%
Basic Shares Outstanding
257.05M 251.53M 246.77M 235.72M
EPS (Diluted)
7.2062 5.1291 1.8326 3.3235
EPS (Diluted) Growth
+70.99% -28.82% -64.27% +81.35%
Diluted Shares Outstanding
259.71M 253.84M 248.83M 237.55M
EBITDA
2.89B 2.08B 1.26B 1.28B
EBITDA Growth
+89.31% -28.08% -39.16% +1.17%
EBITDA Margin
+51.31% +42.74% +31.37% +31.74%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 80.40
Number of Ratings 23 Current Quarters Estimate 1.096
FY Report Date 06 / 2025 Current Year's Estimate 4.267
Last Quarter’s Earnings 1.02 Median PE on CY Estimate N/A
Year Ago Earnings 4.08 Next Fiscal Year Estimate 4.636
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 17 17 20 20
Mean Estimate 1.10 1.13 4.27 4.64
High Estimates 1.12 1.16 4.32 4.82
Low Estimate 1.07 1.10 4.22 4.51
Coefficient of Variance 1.47 1.64 0.57 1.84

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 8
OVERWEIGHT 1 1 1
HOLD 15 16 14
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Hold Overweight

Insider Actions for Hologic Inc. - HOLX

Date Name Shares Transaction Value
Mar 3, 2025 Christiana Stamoulis Director 47,336 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Nanaz Mohtashami Director 4,181 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Ludwig N. Hantson Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Ludwig N. Hantson Director 12,956 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Stacey D. Stewart Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Stacey D. Stewart Director 5,168 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Christiana Stamoulis Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Amy A. McBride-Wendell Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Amy A. McBride-Wendell Director 22,594 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Charles J. Dockendorff Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Charles J. Dockendorff Director 3,436 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Martin D. Madaus Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Martin D. Madaus Director 2,206 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Nanaz Mohtashami Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 13, 2025 Mark W Horvath Div. Pres., Breast & Skeletal 2,844 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 13, 2025 Mark W Horvath Div. Pres., Breast & Skeletal 7,057 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 8, 2024 Stephen P. MacMillan Chairman, President and CEO; Director 1,276,122 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 8, 2024 Erik S. Anderson Div. Pres., Breast & Skeletal 20,639 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 8, 2024 Karleen Marie Oberton Chief Financial Officer 107,752 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 8, 2024 Jan Verstreken Group President, International 103,675 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Hologic Inc. in the News